Drug intelligence / Profile preview

ZeroVIL

Development stage: Preclinical
Lead developer: metaX Institut für Diätetik
Administration: Oral

Overview

ZeroVIL (marketed as "Zero minis") is a range of protein substitute tablets developed by metaX Institut fuer Diatetik GmbH. It is intended for the dietary management of children over 7 years old diagnosed with rare metabolic diseases, including Tyrosinaemia Type I, II, III, Alkaptonuria, Homocystinuria, or Maple Syrup Urine Disease (MSUD). The product aims to provide essential protein while managing the specific dietary restrictions required for these conditions.

Brand names: Zero minis

Beyond the preview

Go deeper on ZeroVIL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZeroVIL.

Explore the full profile